Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Marco Caminati and Francesco Menzella.
Marco Caminati
Connection Strength
1.536
Francesco Menzella
  1. Severe refractory asthma: current treatment options and ongoing research. Drugs Context. 2018; 7:212561.
    View in: PubMed
    Score: 0.798
  2. Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respir Med. 2021 01; 176:106261.
    View in: PubMed
    Score: 0.229
  3. Targeting eosinophils: severe asthma and beyond. Drugs Context. 2019; 8:212587.
    View in: PubMed
    Score: 0.208
  4. Precision Medicine in Targeted Therapies for Severe Asthma: Is There Any Place for "Omics" Technology? Biomed Res Int. 2018; 2018:4617565.
    View in: PubMed
    Score: 0.193
  5. COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy. 2021 03; 76(3):871-874.
    View in: PubMed
    Score: 0.056
  6. Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation. Allergy. 2019 12; 74(12):2539-2541.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.